R. W. Johnstone

RNA decay defines the therapeutic response to transcriptional perturbation in leukaemia

The paper shows that mRNA decay rates determine the effectiveness of transcriptional inhibitors in leukemia, with short-lived mRNAs being more responsive and long-lived ones being modulated by RNA-binding proteins.

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells

This study shows that inhibiting mutant IDH1 in AML promotes leukemic stem cell cycling and sensitizes the disease to azacitidine, suggesting a combination therapy approach.

Inhibition of pyrimidine biosynthesis targets protein translation in AML.

This study shows that DHODH inhibitors block protein translation in AML by reducing YY1 and enhance AML treatment while sparing normal blood cells.

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

This paper identifies BET bromodomain inhibitors as agents that enhance anti-tumor immunity by sensitizing tumors to TNF-mediated cytotoxicity through suppression of NF-κB signaling.

Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia

This study identifies serine metabolism as a vulnerability in FLT3-ITD AML, showing that targeting serine synthesis enhances chemotherapy efficacy.

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.

Efficient CRISPR/Cas9 gene ablation in uncultured naive mouse T cells for in vivo studies

This paper demonstrates efficient CRISPR/Cas9 gene ablation in uncultured naive mouse T cells for in vivo studies, showing gene deletion occurs independently of T cell activation.